Modality
siRNA
MOA
BCMA ADC
Target
SOS1
Pathway
Hedgehog
GACTCL
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
~Aug 2020
→ ~Nov 2021
NDA/BLA
~Feb 2022
→ ~May 2023
Approved
Aug 2023
→ Dec 2030
ApprovedCurrent
NCT08353120
1,237 pts·CTCL
2025-09→2026-01·Not yet recruiting
NCT06735727
1,030 pts·GA
2024-12→2030-12·Completed
NCT05646988
323 pts·CTCL
2023-08→2025-03·Completed
2,590 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-03-171.0y agoPh3 Readout· CTCL
2026-01-123mo agoPh3 Readout· CTCL
2030-12-144.7y awayPh3 Readout· GA
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Approved
Complet…
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2025-03-17 · 1.0y ago
CTCL
Ph3 Readout
2026-01-12 · 3mo ago
CTCL
Ph3 Readout
2030-12-14 · 4.7y away
GA
CompletedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08353120 | Approved | CTCL | Not yet recr... | 1237 | PANSS |
| NCT06735727 | Approved | GA | Completed | 1030 | ACR20 |
| NCT05646988 | Approved | CTCL | Completed | 323 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα | |
| Fixaosocimab | TG Therapeutics | Phase 2/3 | SOS1 | |
| Zanurapivir | Immunocore | Phase 1 | SOS1 |